Abstract
INTRODUCTION
Double antiplatelet therapy (DAPT), consisting of acetylsalicylic acid (ASA) plus an inhibitor of the adenosine diphosphate (ADP) receptor P2Y 12 , is today recommended for coronary artery disease patients both after percutaneous coronary stent implantation and following an acute coronary syndrome [1] . These medications imply the risk of increased postoperative bleeding when patients undergo coronary artery bypass grafting (CABG) [2, 3] . Two frequently employed P2Y 12 inhibitors, clopidogrel and ticagrelor, differ importantly due to the different binding sites on the ADP receptor, different pharmacokinetics and pharmacodynamics [4, 5] . Although better documented for clopidogrel than for ticagrelor, considerable variability is known to exist in patients' response to antiplatelet drugs, both in terms of maximal achievable efficacy and in terms of platelet function recovery after withdrawal [5, 6] . Besides this heterogeneity, other sources of variation in bleeding risk include patient's coagulative diathesis, individual response to cardiopulmonary bypass-related platelet injury and coagulopathy, technical aspects of surgical procedures and of perioperative blood management [7] .
Based on pharmacological considerations, the official guidelines recommend 5 days as minimum optimal time for discontinuation of P2Y 12 inhibitors before CABG [1] . According to the 2011 update to the Society of Thoracic Surgeons and Society of Cardiovascular Anesthesiologists guidelines for blood management, the withdrawal interval may be as short as 3 days for irreversible inhibitors of the P2Y 12 platelet receptor (e.g. clopidogrel) [8] . This concept however was not included in more recent documents, e.g. the 2012 recommendations from the Society of Thoracic Surgeons for antiplatelet drugs use in patients undergoing surgery [9] and the 2014 European Society of Cardiology guidelines on myocardial revascularization [1] .
Recent studies have investigated the capability of different types of point-of-care platelet function (aggregometry) tests to predict the risk of postoperative bleeding in CABG patients, advocating the use of those tests in routine practice [6, [10] [11] [12] [13] [14] [15] . The principal aim of the present study was to report on the results of our routine aggregometry-guided strategy for surgical timing in CABG patients receiving preoperative DAPT. We also tested the hypothesis that aggregometry test results may predict postoperative bleeding, at least in a subset of DAPT patients, independently of other variables, including the discontinuation time interval.
MATERIALS AND METHODS

Patient population
This was a single-centre prospective observational study: data of 322 consecutive patients operated on between June 2013 and November 2015 for isolated first-time CABG by 2 different surgeons employing homogeneous techniques of CABG and surgical haemostasis were collected. Causes for exclusion from the present analysis were single antiplatelet therapy with ASA (47 patients) or off-pump CABG (49 patients). Therefore, 226 patients were included: before being given surgical indications, 140 of them (62%) were on DAPT with ASA + C (100 mg ASA + 75 mg clopidogrel/day), 86 (38%) with ASA + T (100 mg ASA + 90 mg ticagrelor twice/day). Our centre's routine antiplatelet protocol consisted of not discontinuing ASA and trying to operate on patients after at least 72 h (3 days) of P2Y 12 inhibitor withdrawal, preferably 5 days [1, 4, 8, 16, 17] . This study was undertaken to explore the possibility to predict postoperative bleeding basing on aggregometry test results, in a way to individually tailor the discontinuation time. In particular, preoperative ADP tests were performed the day before the scheduled operation, and if the result was <31 U (high-risk cut-off) the operation was delayed; if it was >46 U (safety cut-off), the operation was confirmed for the day after; for results falling between the 2 cut-offs, the operation was postponed to wait for >46 U, unless the operator deemed the disease too severe to allow a safe waiting or, in the presence of a borderline result, a further increase towards the safety cut-off was expected for the day after. However, due to clinical considerations (e.g. severity of coronary disease, unstable clinical picture, etc.), in a proportion of patients, surgery could not be delayed per protocol [8, 13, 16] . The study was approved by the local ethics committee, and patients gave informed consent to participate.
Perioperative management
In all DAPT patients scheduled for CABG, aggregometry was prospectively performed at several preoperative time points (starting on admission, the day of P2Y 12 inhibitor withdrawal), including at induction of anaesthesia, by means of multiple electrode MultiplateV R impedance analyser (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on whole blood samples. All patients had platelet count >100/10 9 l at the time of aggregometry. Both the ASPI test and the ADP test were performed. Aggregometry had not been performed before admission to our Institution in any case. All operations were performed in normothermia, with standard extracorporeal circulation methods (membrane oxygenators, roller pumps, heparinization until activated clotting time >480 s, minimum admitted haematocrit during cardiopulmonary bypass 21% otherwise intraoperative transfusion of packed red blood cells) and cold blood cardioplegia. Tranexamic acid was administered (15 mg/kg) both at anaesthesia induction and after giving protamine. In no patient in the present series was administration of coagulation factors or fresh frozen plasma necessary during the operation.
Study variables
Variables taken into consideration in the analysis included patients' baseline features (age, sex, height, weight and body surface), comorbidities (hypertension, diabetes, obstructive artery disease, chronic pulmonary disease, renal insufficiency and liver disease), type of DAPT (ASA + C or ASA + T), discontinuation time interval (0-3 days or > _4 days), operative variables (number of grafts, cardiopulmonary bypass time and cross-clamp time), postoperative administration of coagulation factors (yes/no) and blood products (yes/no). For the present analysis, last (at induction of anaesthesia) aggregometry test results were treated as both continuous variables and categorized: according to the manufacturer indications, an ADP test > _46 U was considered as the safety cut-off, corresponding to the bottom value of the therapeutic window [18] . An ADP test result of <31 U in our practice indicates high bleeding risk [10] . The safety cut-off for the ASPI-test was 40 U, and a result <30 U indicated strong cyclooxygenase inhibition.
The study end-points were drainage amount at 6, 12 and 24 postoperative hours and increased bleeding, a dichotomic variable defined as drainage amount at 6 postoperative hours falling within the 75th percentile of its distribution [12] . According to this criterion, 'bleeders' in this study were patients whose 6-h blood losses exceeded 450 ml; we chose the 6-h time point, for the cut-off, to rule out the effect of interventions (blood product transfusions, administration of coagulation factors and surgical re-exploration) usually adopted in patients showing increased bleeding in the early postoperative hours. We also compared bleeders to non-bleeders in terms of transfusion and coagulation factors administration.
Statistical analysis
Statistical analysis was performed with the software IBM SPSS Statistics for Windows, Version 21.0 (IBM Corporation, Armonk, NY, USA). All continuous variables were tested for normality of distribution and presented as mean ± standard deviation if normally distributed (e.g. ADP test results), otherwise median and interquartile range (e.g. ASPI test results). Categorical variables were summarized as counts and percentages. Univariable analyses (Mann-Whitney test) were performed to assess differences in terms of postoperative blood losses between treatment groups and between withdrawal interval or ADP test subgroups. Similarly, univariable associations of pre-and intraoperative variables with increased bleeding (>450 ml at 6 h) were sought for by means of the unpaired t-test (in case of normal distribution) or Mann-Whitney test (in case of asymmetric distribution) for continuous variables and v 2 test for categorical variables. Correlations between aggregometry test results and blood losses were analysed by Spearman's rho test. All variables significantly associated with the end-points in univariable analysis (2-tailed significance at P < 0.05) were introduced in multivariable logistic regression models (predicting increased bleeding, >450 ml at 6 h) and in multivariable linear regression models (predicting blood losses amount) as covariates, using the forward stepwise development method. The discrimination of the logistic models was tested by calculation of the area under the receiver operating characteristic curve.
RESULTS
Baseline characteristics of the study patients, both as a whole and divided according to the type of DAPT are presented in Table 1 . Apart from recent myocardial infarction being more frequent in the history of ASA + T patients, all other preoperative variables showed no significant differences between the 2 groups. As far as the bleeding-related variables are concerned (Table 2) , the last ADP test result prior to undergoing surgery was slightly higher in ASA + T patients compared with ASA + C patients, however a similar proportion of patients showed inhibited ADP-dependent aggregation at the time of surgery in the 2 groups. Low median bleeding amounts at 6, 12 and 24 postoperative hours and low rates of transfusion of packed red blood cells and administration of coagulation factors were observed ( Table 2) .
Discontinuation of double antiplatelet therapy
In the overall study population, when withdrawal interval was > _4 days, mean ADP test results were higher (P = 0.003) and drainage amounts were lower (e.g. P = 0.025 at 6 h). The ADP test results and the amount of blood losses stratified according to the withdrawal interval in the 2 groups are shown in Table 3 . Reflecting our routine use of aggregometry tests to guide the surgical timing, the mean ADP test result was beyond the safety cut-off (>46 U) both in the group with longer and in the one with shorter P2Y 12 inhibitor discontinuation (Table 3) . Importantly, the association of lower blood losses with longer withdrawal interval was significant in the ASA + T group only (Table 3) .
Platelet aggregometry tests
In the overall study cohort, an ADP test <46 U was associated with significantly greater blood losses at all 3 time points [e.g. at 6 h: 420 (255-555) vs 300 (220-400) ml, P = 0.001). Significance was confirmed for the 6-h time point only in the ASA + T group, in both groups for the other time points (Fig. 1 ). Blood losses were significantly greater when the preoperative ASPI test was <40 U [e.g. in the ASA + C group at 6 h: 400 (280-490) vs 285 (187-400) ml, P = 0.001; in the ASA + T group at 6 h: 310 (250-480) vs 230 (157-305) ml, P < 0.0001].
Regarding Spearman's correlations between preoperative ADP test and postoperative blood losses, the highest correlation coefficient was found for the ASA + T group at 6 h, while correlations of blood losses with ADP test in the ASA + C group were weaker, though significant, as were correlations with ASPI test in both groups (Fig. 2) . The correlations between ADP test and ASPI test were moderate but significant in both groups (r s = 0.52 in ASA + C, r s = 0.49 in ASA + T; both P < 0.001). Figure 3 shows the distribution of patients defined as 'bleeders' when plotted according to ADP test and ASPI test results, in the 2 treatment groups: in the ASA + T group they were concentrated quite homogeneously in the plot area corresponding to ADP test <46 U and ASPI test <40 U, whereas in the ASA + C 
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group, 26% of patients with ADP test >46 U presented increased bleeding. In the ASA + T group, patients with recovered ADPdependent aggregation (ADP test >46 U) had increased bleeding (>450 ml) significantly less often than those operated on under inhibited ADP-dependent aggregation (8% vs 40%, P = 0.002); this difference was barely significant in the ASA + C group (26% vs 44%, P = 0.053). Among bleeders, red blood cell transfusions and administration of coagulation factors occurred 3-4 times more frequently than in non-bleeders (P < 0.001). Only 2 patients (0.9%), both bleeders, received platelet transfusion (P = 0.064). Postoperative mortality was 2.7% in the overall cohort: in transfused patients, it was 6% (P = 0.063).
Predictors of bleeding
Of all the other tested variables (listed in Table 1 ), only male sex was associated in univariable analysis with significantly greater amounts of blood losses (versus female: P = 0.024 at 6 h, P = 0.003 P-values are in italics when statistically significant (P < 0.05). at 12 h, P = 0.002 at 24 h). Body surface area and cardiopulmonary bypass time showed no correlation with blood losses.
In multivariable linear regression analysis (Table 4) , including patient's sex, withdrawal time, ASPI test result and ADP test result as covariates, the ADP test was the only independent predictor of blood losses at 6 h in the ASA + T group, the ASPI test in the ASA + C group. These predictors were confirmed in models predicting 12-h and 24-h blood losses.
Also in multivariable logistic regression analysis (Table 4) , searching for independent predictors of blood losses >450 ml at 6 h (75th percentile), the only significant predictor was ADP test for the ASA + T group (area under the receiver operating characteristic curve: 0.81); ASPI test for the ASA + C group (area: 0.70). In the whole study population, the 'bleeder' status was independently predicted by the ADP test as well (P = 0.022), with ASPI test barely approaching significance (P = 0.051): area under the curve 0.73, 95% confidence interval 0.65 to 0.81 (Fig. 4) .
DISCUSSION
Postoperative bleeding in patients undergoing CABG represents a particular concern: haemorrhagic complications can importantly Figure 4 : Receiver operating characteristic curve of the logistic regression model predicting increased bleeding (75th percentile of blood losses at 6 h: >450 ml) in the overall study population. AUC = area under the curve.
impair the postoperative course of CABG patients, by increasing the risk of transfusions and therefore of transfusion-related morbidity [19] . Surgical re-entry for bleeding affects not only early post-CABG outcomes but also survival beyond 90 postoperative days [20] . Considering that DAPT is recommended for a considerable proportion of coronary artery disease patients, there has been vivid investigation on whether and when antiplatelets should be discontinued before surgery, to avoid excess bleeding [16, 21] . Studies focusing on the role that point-of-care aggregometry tests can play to this purpose have provided encouraging results [11] [12] [13] [14] [15] 22] . So far, several studies had assessed the effect of different withdrawal times on bleeding risk [2, 16, 17, 21] , without considering point-of-care tests; others have addressed the predictive role of aggregometry tests, however without comparing different withdrawal times [11] [12] [13] [14] . Most studies have addressed only one type of P2Y12 inhibitor [12] [13] [14] . Conversely, here we took into account both factors of length of discontinuation and results of preoperative aggregometry tests and assessed which factor had an independent predictive role, separately in ASA + C and ASA + T patients.
Since the introduction of preoperative aggregometry in our routine CABG practice, we have been trying to operate on stable patients when the ADP test values were at least >31 U [10] and if possible (i.e. based on clinical considerations) >46 U, according to the analyser manufacturer's indication [18] . This policy explains the low number of patients with low ADP test values and with short discontinuation time in this series. Our scheduling of surgical sessions is performed weekly, however adjustments are done on a daily basis as waiting patients' conditions change: in some patients, in the present study, the operation had to be performed notwithstanding persistent inhibition of platelet function as demonstrated by the ADP test. In a majority of such cases, the reason resided on ischaemic instability and/or severity of coronary lesions (either at first presentation-emergency-or after a first period of admission and drug discontinuation-urgent cases), while in a few others on logistics and organizational issues. On this basis, various combinations of withdrawal period length and level of anti-aggregation are represented in our study population, allowing for a multifactorial analysis of the determinants of bleeding.
The present results show that routinely using ADP tests, we achieved low rates of bleeding and very low rates of transfusions and pro-coagulative drugs administration. For comparison, in a previous study performed at our centre, including more than 1000 CABG patients, we had an overall postoperative transfusion rate of 46%, mean blood loss volume of >700 ml/24 h and a reexploration rate of 2.4% [23] . Indeed, would have we followed the Universal Definition of Postoperative Bleeding [24] in the present study, the number of severe 'bleeders' would have been so low that any statistical analysis of determinants would have been underpowered. Therefore, we chose to adapt our definition of 'bleeders' to the context, using the criterion of the 75th percentile of 6-h drainage amounts [12] . A 'sensitive' cut-off for definition of bleeders resulted, i.e. 450 ml at 6 h: however, aggregometry tests proved capable to predict bleeding amount even in the low range, and a significant difference was found in terms of transfusions and mortality between bleeders and non-bleeders. Withdrawal intervals were categorized as 0-3 days or > _4 days, instead of using 2 different cut-offs for ASA + C and ASA + T, based on the evidence that, regardless of purely pharmacological notions, in most studies, the rates of bleeding complications with both ticagrelor and clopidogrel deflect around 72 h of discontinuation [2, 4, 16, 17] : although a further decrease in bleeding is observed after >120 h for clopidogrel [2] , the focus of the present study was on the role of aggregometry. That study however did not employ aggregometry tests: in the present analysis, with < _72 h discontinuations half of ASA + C patients and nearly one-third of ASA + T patients had a preoperative ADP test showing recovery of ADP-mediated aggregation (Table 3) , which allowed decreasing their waiting time. A larger study population than the present one is required to confirm the magnitude of this advantage.
As regards the differences between the 2 treatment groups, in the ASA + C, the association of longer discontinuation with smaller drainage amounts was not significant, a phenomenon probably driven by greater individual variability in functional recovery of platelets than with ticagrelor. Consistent with our data, a previous study focusing only on clopidogrel [12] observed poor correlation between duration of clopidogrel withdrawal and ADP test values.
Another interesting result was that the ADP test was a better predictor of bleeding in the ASA + T group, the ASPI test in the ASA + C group. While the predictive role of ADP test for ticagrelor had been already pointed out by Malm and colleagues [14] , the result in the ASA + C group is consistent with a report by Kuliczkowski and associates [22] , who found that the ASPI test (using a cut-off equivalent to ours) predicted higher postoperative drainage in patients who had received ASA and/or clopidogrel. Petricevic, in an ASA + C cohort, found the ASPI test to be the only predictor of postoperative transfusions [12] . Figure 2 suggests the 46 U cut-off of ADP test as an index for identification of bleeders among ASA + T patients, unlike in the ASA + C group, where however very few bleeders had an ASPI test >40 U, implying that a combination of both tests could be helpful in case of ASA + C: this hypothesis, based on the known synergic activity of clopidogrel and ASA, would deserve further investigation.
Limitations
The present study has some limitations that should be acknowledged. Firstly, we had data on postoperative aggregometry only for a proportion of patients; therefore, we could not reliably assess the effect of postoperative platelet inhibition, on whom the cardiopulmonary bypass and other procedure-related factors can exert important influence [7, 25] . However, in univariable analysis, limited to the available data, the postoperative tests showed weaker correlation with blood losses (data not shown). Secondly, we did not perform the aggregometry test exploring platelet response to thrombin (TRAP test), so we lack this type of potentially interesting information, especially in patients with very low ADP test value [11] . Thirdly, since the study focus was on the potential value of aggregometry tests, rather than discontinuation time duration, in predicting bleeding, data on discontinuation time was collected only in the format of a categorical variable, therefore, it was not possible to treat it as a continuous variable in the analysis. Finally, for correct interpretation of the findings in this study, it is important to recognize that the surgeons performing CABG were not blinded to the type of DAPT and to the results of preoperative aggregometry tests: surgical efforts in haemostasis could have been possibly influenced by this information.
CONCLUSION
In conclusion, by routinely applying a strategy of aggregometryguided surgical timing in CABG patients receiving preoperative DAPT, bleeding amounts and rates of transfusion can be notably controlled. Aggregometry tests provide a good prediction of the bleeding risk. Prediction by ADP test seems more reliable for ASA + T therapy, whereas a combination of ASPI test and ADP test could be better used for ASA + C. Further expansion of this research will be devoted to verify the hypothesis that in patients needing urgent operation while at high bleeding risk according to the tests, measures of bleeding prevention and/or treatment can be undertaken in a more timely fashion, thus positively affecting the overall post-CABG outcome [19] .
